Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.
Rischin, D; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; Castro, G; Psyrri, A; Baste, N; Neupane, PC; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Lin, JX; Gumuscu, B; Swaby, RF; Burtness, B J CLIN ONCOL. 2020; 38(15):
Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX
Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM ANN ONCOL. 2020; 31: S949-S950.
Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE (R)) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
Tran, B; Horvath, L; Dorff, T; Rettig, M; Lolkema, MP; Machiels, JP; Rottey, S; Autio, K; Greil, R; Adra, N; Lemech, C; Minocha, M; Cheng, FC; Kouros-Mehr, H; Fizazi, K ANN ONCOL. 2020; 31: S507-S507.
S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – first results of the international MATEO trial initiated by the AIO
Haag, GM; Stocker, G; Lorenzen, S; Ettrich, T; Munoz, FL; Kiani, A; Venerito, M; Trojan, J; Mahlberg, R; Moosmann, N; Chibaudel, B; Kubicka, S; Greil, R; Daum, S; Geissler, M; Mann, J; Lordick, F ONCOL RES TREAT. 2020; 43(SUPPL 4): 156-156.
Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
Chao, J; Buxo, E; Cervantes, A; Dayyani, F; Lima, CMSR; Greil, R; Van Laarhoven, HWM; Lorenzen, S; Heinemann, V; Kischel, R; Shitara, K; Lordick, F J CLIN ONCOL. 2020; 38(15):
Reporting a Case on Good Response of Lupus Hepatitis to Mycophenolate Mofetil and Belimumab as of Lupus Exanthema to Rituximab.
Psenak, O; Studnicka-Benke, A; Haufe, H; Greil, R; In: Book Publisher International editors(s). Current Topics in Medicine and Medical Research. 9: Hooghly, West Bengal, India: Sciencedomain; p. 158-164. (ISBN: 978-93-90431-50-2)
Systemischer Lupus erythematodes
Oskar Psenak Fortbildung für das Ärzteteam; 21.10.2020; Großgmain. 2020.
Rheuma trifft Lunge – Der ILD-Patient im Fokus_x000D_ Überblick + Kasuistik_x000D_
Oskar Psenak Rheuma trifft Lunge – Der ILD-Patient im Fokus_x000D_ ; 24.09.2020; Salzburg. 2020.
Fallbericht – Cosentyx bei Morbus Bechterew_x000D_
Oskar Psenak Erstlinientherapie des Morbus Bechterew mit Secukinumab; 26.06.2020; virtuelle Konferenz. 2020.
Mit Baricitinib langanhaltende Remission erzielen
Oskar Psenak Rheuma Plus. 2020. 1-2.
